Details

Autor(en) / Beteiligte

• Granger, Christopher B
• Alexander, John H
• McMurray, John J.V
• Lopes, Renato D
• Hylek, Elaine M
• Hanna, Michael
• Al-Khalidi, Hussein R
• Ansell, Jack
• Atar, Dan
• Avezum, Alvaro
• Bahit, M. Cecilia
• Diaz, Rafael
• Easton, J. Donald
• Ezekowitz, Justin A
• Flaker, Greg
• Garcia, David
• Geraldes, Margarida
• Gersh, Bernard J
• Golitsyn, Sergey
• Goto, Shinya
• Hermosillo, Antonio G
• Hohnloser, Stefan H
• Horowitz, John
• Mohan, Puneet
• Jansky, Petr
• Lewis, Basil S
• Lopez-Sendon, Jose Luis
• Pais, Prem
• Parkhomenko, Alexander
• Verheugt, Freek W.A
• Zhu, Jun
• Wallentin, Lars

Titel

Apixaban versus Warfarin in Patients with Atrial Fibrillation

Ist Teil von

• The New England journal of medicine, 2011-09, Vol.365 (11), p.981-992

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2011

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The oral direct factor Xa inhibitor, apixaban, was compared with warfarin in atrial fibrillation. Apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and lowered mortality. Patients with atrial fibrillation are at increased risk for stroke. Warfarin and other vitamin K antagonists are highly effective treatments, reducing the risk of stroke by about two thirds, but their use is limited by a narrow therapeutic range, drug and food interactions, required monitoring, and risk of bleeding. 1 A randomized trial has confirmed the effectiveness of warfarin in the current era. 2 Two new oral anticoagulants have recently been shown to be equivalent or superior to warfarin in preventing stroke or systemic embolism. 3 , 4 Apixaban is a direct oral factor Xa inhibitor with rapid absorption, a 12-hour half-life, and 25% . . .